984
Index
Hydroxyurea, 222, 775, 777, 787,
789–790
Hydroxyzine, 853, 854
Hyoscine, 501, 503, 927
Hyoscyamine, 501, 503
Hyperaldosteronism, 803, 813
Hypercalcaemia, 551, 554, 563, 564
Hyperglycaemia, 36–37, 572, 578
Hyperkalaemia, 37, 803
Hyperlipidaemia, 729, 730, 733
treating, 734–735
Hyperparathyroidism, 551, 563–564
secondary, 564
Hypersensitivity, 31, 33
anti-infective agents, 87
Hypertension, 652, 660–661
antihypertensive agents.
See
Antihypertensive agents
pulmonary arterial, 664
treating, 662, 664, 667
initiating therapy, 672–674
safe medication administration, 671
“white coat”, 661
Hyperthyroidism, 551, 555, 556
Hypertonia, 385, 388
Hypertonic solution, 77
Hypnosis, 303, 305
Hypnotic agents.
See
Anxiolytic and
hypnotic agents
Hypocalcaemia, 551, 554, 563–569
Hypoglycaemia, 36, 572, 578
Hypogonadism, 627, 629
Hypokalaemia, 37, 809
Hypoparathyroidism, 551, 563–569
Hypopituitarism, 521, 525
Hypotension, 652, 657, 661–662
Hypothalamic and pituitary agents,
521–534
adults, 523
agonists, 521, 523
children, 523
drugs affecting anterior pituitary
hormones, 521, 525–530
growth hormone agonists.
See
Growth
hormone agonists
growth hormone antagonists.
See
Growth hormone antagonists
drugs affecting hypothalamic
hormones, 521, 522–525
adverse effects, 524
care considerations, 524
contraindications and cautions, 524
pharmacokinetics, 524
therapeutic actions and indications,
523–524
drugs affecting posterior pituitary
hormones, 521, 530–533
adverse effects, 533
care considerations, 533
contraindications and cautions,
532–533
drug–drug interactions, 533
pharmacokinetics, 532
therapeutic actions and indications,
530
older adults, 523
Hypothalamic hormones, 516
agonists, 524
antagonists, 524
drugs affecting, 521, 522–525
adverse effects, 524
care considerations, 524
contraindications and cautions, 524
pharmacokinetics, 524
therapeutic actions and indications,
523–524
Hypothalamic–pituitary axis (HPA), 512,
517
Hypothalamus, 512, 514–515
Hypothyroidism, 551, 554–556
critical thinking scenario, 558–560
Hypotonic solution, 77
Hyssop, 965
I
Iatrogenesis, 31, 39
Ibandronate, 566, 567
Ibuprofen, 241, 247, 250
Idarubicin, 205, 206
Ifosfamide, 195, 197
Imatinib, 191, 194, 219–222
Imipramine, 316, 317, 318, 320, 321
Imiquimod, 146, 147, 951
Immune modulators, 258–269
adults, 260
children, 260
immune stimulants, 258, 259–261
care considerations, 262–263
interferons.
See
Interferons
interleukins.
See
Interleukins
immune suppressants, 258, 263–266
anakinra, 253–255, 264, 266
care considerations, 267–268
monoclonal antibodies, 258, 263–267
T- and B-cell suppressors, 263–266
older adults, 260
sites of action, 259
Immune response and inflammation,
228–238
barrier defences, 229–230
gastric acid, 229
major histocompatibility complex,
228, 229–230
mucous membranes, 229
skin, 229
cellular defences, 230–231
basophils, 230
eosinophils, 230
lymphoid tissues, 231
monocytes/macrophages, 228,
230–231
neutrophils, 230
immune response, 233–235
antibody formation, 234–235
B cells, 233–234
complement proteins, 234
interferons, 235
interleukins, 235
T cells, 233–234
thymosin, 235
tumour necrosis factor (TNF), 235
inflammatory response, 231–233
chemotaxis, 231–232
clinical presentation, 232–233
histamine release, 231
kinin system, 231
interrelationship, 235–237
pathophysiology, immune system,
237–238
autoimmune disease, 238
neoplasms, 237–238
transplant rejection, 238
viral invasion of cells, 238
Immune sera, 272, 285–288
adverse effects, 287
care considerations, 287–288
contraindications and cautions, 287
drug-drug interactions, 287
immunoglobulin, normal, 273, 286,
287
pharmacokinetics, 285
therapeutic actions and indications, 285
Immune stimulants, 258, 259–261
interferons.
See
Interferons
interleukins.
See
Interleukins
Immune suppressants, 258, 263–267
anakinra, 253–255, 264, 265
care considerations, 267–268
monoclonal antibodies, 258, 263–266
T- and B-cell suppressors, 263–266
Immune system
drugs acting on
anti-inflammatory, antiarthritis
and related agents.
See
Anti-
inflammatory, antiarthritis and
related agents
immune modulators.
See
Immune
modulators
vaccines and sera.
See
Vaccines and
sera
pathophysiology involving the immune
system, 237–238
autoimmune disease, 238
neoplasms, 237–238
transplant rejection, 238
viral invasion of cells, 238
Immunisation, 272, 273–278
National Schedules
Australia, 275–276
New Zealand, 277
paediatric, 278
Immunity, 273
Immunoglobulin.
See
Immune sera
Immunological factors
drug effects and, 25, 26–27
Impinem-cilastin, 97, 98
Implementation, 42, 45
Incretins, 572, 573, 574, 575, 587, 588
Indacaterol, 867, 871–872
Indapamide, 675, 805, 807
Indinavir, 136, 139
Indomethacin, 241, 247
Induction, 416, 419
Infiltration, anaesthesia, 424
Inflammation.
See also
Immune response
and inflammation
inflammatory response, 231–233, 240
chemotaxis, 231–232
